Silihan lan utang jangka dawa perusahaan: Tonix Pharmaceuticals Inc. (TNXP)

Tonix Pharmaceuticals (TNXP) manages a portfolio of anti-infective and pain management agents, leveraging the adaptation of legacy formulas for new niches. The market dynamics reflected in the price action on GURU.Markets show the 0.00 indicator. Tonix Pharmaceuticals (TNXP) relies on the development of CNS drugs, where patent protection ensures sustained interest in chronic disease therapies. The business is currently undergoing a rigorous restructuring, concentrating capital on final-stage trials to maintain solvency.

This indicator reflects the obligations of Tonix Pharmaceuticals (TNXP) with maturities exceeding twelve months, which depend on credit policy and market rates. In fundamental analysis, this metric measures the level of long-term financial burden and the extent of the business's reliance on borrowed capital. By analyzing the company's long-term debt structure, an investor assesses the risk of macroeconomic sensitivity. For Tonix Pharmaceuticals (TNXP), such loans are critical for financing capital-intensive R&D projects in the fields of neurobiology and vaccination.